• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助化疗后病理缓解的食管鳞癌患者的残留疾病分布和复发模式。

Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.

机构信息

Department of Surgery, Keio University School of Medicine, Tokyo, Japan.

Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

出版信息

Ann Surg. 2022 Aug 1;276(2):298-304. doi: 10.1097/SLA.0000000000004436. Epub 2020 Oct 16.

DOI:10.1097/SLA.0000000000004436
PMID:33074909
Abstract

OBJECTIVE

This study aimed to elucidate the residual disease distribution and recurrence patterns in patients with ESCC responding to NAC.

SUMMARY BACKGROUND DATA

To appropriately plan a prospective trial for the organ preservation approach which includes additional chemoradiotherapy in patients who responded to NAC, the distribution of residual disease needs to be elucidated. Given that the residual tumor is located in the regional field, chemoradiotherapy can be safely added to eliminate the residual disease.

METHODS

Overall, 483 patients with resectable ESCC who received NAC followed by transthoracic esophagectomy at 2 high-volume centers were reviewed. The recurrence-free survival, overall survival (OS), and residual and recurrent tumor patterns were compared among the pathological responses.

RESULTS

Compared with nonpathological responders, pathological responders exhibited significantly longer recurrence-free survival [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.25 ( P < 0.001)/0.17 ( P < 0.001)/0.16 ( P = 0.003)] and OS [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.26 ( P < 0.001)/0.12 ( P < 0.001)/0.11 ( P = 0.003)]. In terms of the distribution of recurrence, the percentages of solitary recurrence in the regional field out of all recurrence was significantly higher in patients with Grade 1b (60%)/2 (67%)/3 (67%) whereas less than 25% in Grade 0 or 1a.

CONCLUSIONS

It was found that postoperative recurrence in responders occurred in the regional field mostly as a solitary lesion without the distant failure, indicating that the residual tumor cells can be eliminated by additional chemoradiotherapy.

摘要

目的

本研究旨在阐明对新辅助化疗(NAC)有反应的食管鳞癌(ESCC)患者的残留疾病分布和复发模式。

背景概要数据

为了适当规划针对包括对 NAC 有反应的患者在内的器官保存方法的前瞻性试验,需要阐明残留疾病的分布情况。鉴于残留肿瘤位于区域内,可安全地添加放化疗以消除残留疾病。

方法

共对 2 家高容量中心的 483 例接受 NAC 治疗后行经胸食管切除术的可切除 ESCC 患者进行了回顾性分析。比较了病理反应患者之间的无复发生存率、总生存率(OS)以及残留和复发性肿瘤模式。

结果

与非病理反应者相比,病理反应者的无复发生存率[1b/2/3 级与 0 级相比的危险比(HR);0.25(P<0.001)/0.17(P<0.001)/0.16(P=0.003)]和 OS[1b/2/3 级与 0 级相比的 HR;0.26(P<0.001)/0.12(P<0.001)/0.11(P=0.003)]显著延长。就复发的分布而言,1b 级(60%)/2 级(67%)/3 级(67%)患者中,区域复发中孤立复发的比例明显高于 0 级或 1a 级(<25%)。

结论

研究发现,有反应者的术后复发主要发生在区域内,多为孤立性病变,无远处失败,提示残留肿瘤细胞可通过额外的放化疗消除。

相似文献

1
Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.新辅助化疗后病理缓解的食管鳞癌患者的残留疾病分布和复发模式。
Ann Surg. 2022 Aug 1;276(2):298-304. doi: 10.1097/SLA.0000000000004436. Epub 2020 Oct 16.
2
A nationwide validation of the prognostic impact of pathological response and the distribution of recurrence patterns in responders after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.一项关于食管鳞状细胞癌新辅助化疗后病理反应的预后影响及反应者复发模式分布的全国性验证研究。
Esophagus. 2023 Apr;20(2):205-214. doi: 10.1007/s10388-022-00962-1. Epub 2022 Nov 1.
3
Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.临床III期食管鳞状细胞癌患者新辅助化疗与先行手术加或不加化疗的比较。
Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12473.
4
Impact of Lymphatic and Venous Invasion Patterns on Postoperative Prognosis and Distant Metastasis in Esophageal Squamous Cell Carcinoma After Preoperative Chemotherapy.术前化疗后食管鳞状细胞癌中淋巴管和静脉侵犯模式对术后预后及远处转移的影响
Ann Surg Oncol. 2025 Feb;32(2):860-871. doi: 10.1245/s10434-024-16522-z. Epub 2024 Nov 22.
5
Clinical Significance of Endoscopic Response Evaluation to Predict the Distribution of Residual Tumor after Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.内镜反应评估对预测食管鳞癌新辅助化疗后残余肿瘤分布的临床意义。
Ann Surg Oncol. 2022 Apr;29(4):2673-2680. doi: 10.1245/s10434-021-11009-7. Epub 2021 Nov 23.
6
Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.新辅助放化疗联合手术治疗食管鳞癌患者的复发模式和时间。
BMC Cancer. 2021 Nov 9;21(1):1192. doi: 10.1186/s12885-021-08918-x.
7
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.新辅助放化疗与新辅助化疗治疗食管鳞状细胞癌的比较:来自中国国家癌症中心的一项倾向评分匹配研究
J Cancer Res Clin Oncol. 2022 Apr;148(4):943-954. doi: 10.1007/s00432-021-03659-7. Epub 2021 May 19.
8
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.新辅助化疗后手术治疗的食管鳞癌患者病理肿瘤反应和残留淋巴结转移的预后意义。
Esophagus. 2019 Oct;16(4):395-401. doi: 10.1007/s10388-019-00679-8. Epub 2019 Jun 12.
9
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.新辅助放化疗后与新辅助化疗后行微创食管切除术的局部晚期食管鳞癌患者的发病率和死亡率:一项随机临床试验。
JAMA Surg. 2021 May 1;156(5):444-451. doi: 10.1001/jamasurg.2021.0133.
10
Multi-Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma.食管鳞状细胞癌新辅助放化疗或放疗后不同病理退缩类型的生存和复发模式的多机构分析
Cancer Med. 2025 Feb;14(4):e70676. doi: 10.1002/cam4.70676.

引用本文的文献

1
Detection of pathologic complete response using deep neural network-based endoscopic evaluation in patients with esophageal cancer receiving neoadjuvant chemotherapy: a nationwide multicenter retrospective study from 46 Japanese esophageal centers.使用基于深度神经网络的内镜评估检测接受新辅助化疗的食管癌患者的病理完全缓解:一项来自日本46个食管癌中心的全国多中心回顾性研究。
Esophagus. 2025 Apr 28. doi: 10.1007/s10388-025-01130-x.
2
An organoid library of human esophageal squamous cell carcinomas (ESCCs) uncovers the chemotherapy-resistant ESCC features.一个人类食管鳞状细胞癌(ESCC)类器官文库揭示了化疗耐药的ESCC特征。
Commun Biol. 2025 Apr 1;8(1):507. doi: 10.1038/s42003-025-07869-4.
3
Correlation Between Histopathological Response of Esophageal Squamous Cell Carcinoma to Neoadjuvant DCF Therapy and the Clinical Efficacy of Palliative Chemotherapy for Recurrence.
食管鳞状细胞癌对新辅助DCF治疗的组织病理学反应与复发后姑息化疗临床疗效的相关性
J Gastrointest Cancer. 2025 Feb 8;56(1):60. doi: 10.1007/s12029-025-01190-3.
4
Remarkable response as a new indicator for endoscopic evaluation of local efficacy of non-surgical treatments for esophageal cancer.显著缓解率作为新指标用于评估非手术治疗食管癌的局部疗效的内镜评价。
Esophagus. 2024 Apr;21(2):85-94. doi: 10.1007/s10388-024-01043-1. Epub 2024 Feb 14.
5
Characterization of residual cancer by comparison of a pair of organoids established from a patient with esophageal squamous cell carcinoma before and after neoadjuvant chemotherapy.通过比较一对源自接受新辅助化疗前后的食管鳞癌患者的类器官来对残留肿瘤进行特征分析。
Hum Cell. 2024 Mar;37(2):491-501. doi: 10.1007/s13577-023-01020-3. Epub 2024 Jan 6.
6
Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial.纳武利尤单抗辅助治疗食管癌:基于 CheckMate 577 试验亚组分析的综述。
Front Immunol. 2023 Oct 4;14:1264912. doi: 10.3389/fimmu.2023.1264912. eCollection 2023.
7
Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response.用于预测治疗反应的功能测试中基于患者的体外培养和具有替代生物标志物的终点测定
Cancers (Basel). 2023 Aug 15;15(16):4104. doi: 10.3390/cancers15164104.
8
Endoscopic Evaluation of Pathological Complete Response Using Deep Neural Network in Esophageal Cancer Patients Who Received Neoadjuvant Chemotherapy-Multicenter Retrospective Study from Four Japanese Esophageal Centers.使用深度神经网络对接受新辅助化疗的食管癌患者进行病理完全缓解的内镜评估——来自四个日本食管癌中心的多中心回顾性研究
Ann Surg Oncol. 2023 Nov;30(12):7472-7480. doi: 10.1245/s10434-023-13862-0. Epub 2023 Aug 5.
9
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.在局部晚期可切除食管鳞癌中的新辅助 adebrelimab:1b 期试验。
Nat Med. 2023 Aug;29(8):2068-2078. doi: 10.1038/s41591-023-02469-3. Epub 2023 Jul 24.
10
The genomic signature of resistance to platinum-containing neoadjuvant therapy based on single-cell data.基于单细胞数据的含铂新辅助治疗耐药的基因组特征
Cell Biosci. 2023 Jun 8;13(1):103. doi: 10.1186/s13578-023-01061-z.